Medically reviewed on September 10, 2018
(tel OH tri state ETH il)
- Telotristat Etiprate
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Xermelo: 250 mg
Brand Names: U.S.
- Tryptophan Hydroxylase Inhibitor
Telotristat ethyl is a small molecule inhibitor of tryptophan hydroxylase (TPH). TPH converts tryptophan to 5-hydroxytryptophan and ultimately to serotonin, and is the rate-limiting enzyme in serotonin synthesis (Kulke 2017). Decreased production of peripheral serotonin by telotristat ethyl results in a reduction in the frequency of carcinoid syndrome diarrhea.
The high molecular weight and acidic moieties of telotristat ethyl inhibit the compound from crossing the blood brain barrier (Kulke 2017).
Telotristat ethyl is hydrolyzed via carboxylesterases to the metabolite telotristat (active); telotristat is further metabolized.
Feces (~93%); urine (<1%)
Time to Peak
Telotristat ethyl: 0.5 to 2 hours; Telotristat: 1 to 3 hours
Telotristat ethyl: ~0.6 hours; Telotristat: ~5 hours
Use: Labeled Indications
Carcinoid syndrome diarrhea: Treatment of carcinoid syndrome diarrhea (in combination with somatostatin analog therapy) in adults with symptoms inadequately controlled by somatostatin analog therapy
There are no contraindications listed within the manufacturer's labeling.
Carcinoid syndrome diarrhea: Oral: 250 mg 3 times daily
Missed dose: If a dose is missed, administer the next dose at the regularly scheduled time; do not take 2 doses at the same time.
Refer to adult dosing.
Dosing: Renal Impairment
CrCl >20 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling; however, population pharmacokinetic analysis suggests that CrCl 20 to 89 mL/minute does not affect telotristat pharmacokinetics.
End-stage renal disease (ESRD) requiring dialysis: There are no dosage adjustment provided in the manufacturer’s labeling (has not been studied).
Dosing: Hepatic Impairment
Mild impairment (total bilirubin >1 to 1.5 times ULN or AST > ULN): There are no dosage adjustments provided in the manufacturer’s labeling; however, population pharmacokinetic analysis suggests that mild hepatic impairment does not affect telotristat pharmacokinetics.
Moderate or severe impairment (total bilirubin >1.5 times ULN and any AST): There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).
Dosing: Adjustment for Toxicity
Gastrointestinal toxicity: Discontinue for severe constipation or for development of severe, persistent or worsening abdominal pain
Administer with food. If used in combination with short-acting octreotide, administer octreotide at least 30 minutes after telotristat ethyl. Rescue octreotide (short-acting) and antidiarrheals were allowed and unrestricted in a clinical study (Kulke 2017).
Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).
CloZAPine: CYP3A4 Inducers (Weak) may decrease the serum concentration of CloZAPine. Monitor therapy
NiMODipine: CYP3A4 Inducers (Weak) may decrease the serum concentration of NiMODipine. Monitor therapy
Octreotide: May decrease the serum concentration of Telotristat Ethyl. Management: Administer short-acting octreotide at least 30 minutes after administration of telotristat ethyl and monitor for decreased telotristat ethyl efficacy. Consider therapy modification
Central nervous system: Headache (11%)
Gastrointestinal: Nausea (13%)
1% to 10%:
Cardiovascular: Peripheral edema (7%)
Central nervous system: Depression (9%)
Endocrine & metabolic: Increased gamma-glutamyl transferase (9%)
Gastrointestinal: Decreased appetite (7%), flatulence (7%), abdominal pain (≥5%), constipation (≥5%)
Hepatic: Increased serum alkaline phosphatase (<5%), increased serum ALT (<5%), increased serum AST (<5%)
Miscellaneous: Fever (7%)
Concerns related to adverse effects:
• Gastrointestinal toxicity: Constipation has been reported in clinical trials. Although rarely serious, some events resulted in hospitalization, intestinal perforation or bowel obstruction (these events occurred at a dose higher than the recommended dose). Patients with advanced carcinoid tumors may be at risk for altered gastrointestinal tract wall integrity; monitor closely for constipation and/or severe, persistent, or worsening abdominal pain. Discontinue for severe constipation and/or the development of severe persistent or worsening abdominal pain.
Monitor for symptoms of constipation and/or severe, persistent, or worsening abdominal pain
Adverse events were observed in some animal reproduction studies.
More about telotristat
- Telotristat Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- Drug class: miscellaneous GI agents
Other brands: Xermelo